Roy Flood, MD
Cardiovascular Disease · Savannah, GANPI 1336124338
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 55 manufacturers reported payments, led by Boehringer Ingelheim at 28.2% of the total. Reporting peaked in 2019 at $42,687 and has fallen 89.4% since, to $4,532 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 910 payments — averaging $95.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$24K
- Lilly USA, LLC$19K
- AstraZeneca$12K
- Shockwave Medical, Inc$9K
- Boston Scientific$4K
- Medtronic$2K
- plus $15K from 49 others
Across 3 payments — averaging $10,922 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$33K
What the payments were for
- Consulting fees$3,7504%
- Speaking & faculty fees$48,68856%
- Travel & lodging$12,45314%
- Food & beverage$21,79725%
- Education$1970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$38,358
- BRILINTA$10,963
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$8,839
- WATCHMAN Access System$2,660
- ONYX FRONTIER$915
- Impella$818
- RESOLUTE ONYX$636
- HMG-CoA reductase inhibitor.$498
- Barostim Neo System$343
- OPTICROSS$264
- UPTRAVI$250
- OPSUMIT$250
- FARXIGA$219
- Indigo System$155
- AVVIGO Guidance System$145
- Repatha$133
- LifeVest$129
- AMVUTTRA$128
- XARELTO$124
- GENERAL - STENTS$122
How this compares
$86,885 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 402 | $443,209 |
| XareltoRivaroxaban | 197 | $237,115 |
| EntrestoSacubitril/Valsartan | 120 | $124,484 |
| FarxigaDapagliflozin Propanediol | 79 | $96,258 |
| Repatha SureclickEvolocumab | 83 | $70,379 |
| JardianceEmpagliflozin | 48 | $43,007 |
| BrilintaTicagrelor | 30 | $25,252 |
| Ranolazine ErRanolazine | 87 | $12,984 |
| OzempicSemaglutide | 11 | $10,306 |
| VascepaIcosapent Ethyl | 13 | $8,357 |
| Metoprolol Succinate | 659 | $7,330 |
| Nitroglycerin PatchNitroglycerin | 93 | $4,811 |
| Atorvastatin Calcium | 463 | $4,104 |
| Nebivolol Hcl | 61 | $3,162 |
| Potassium Chloride | 148 | $3,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $793 | $443,209402 claims |
| Johnson & JohnsonXarelto | $1,373 | $237,115197 claims |
| NovartisEntresto | $1,030 | $124,484120 claims |
| AstraZenecaFarxiga, Brilinta | $12,435 | $121,510109 claims |
| Boehringer IngelheimJardiance | $24,485 | $43,00748 claims |
| Novo NordiskOzempic | $136 | $10,30611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Savannah
- John SpellmanSavannah$30K
- Abdul Razaq AdeniyiSavannah$27K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.